AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
ReutersAug 12, 2025 11:31 AM
Aug 12 (Reuters) - AN2 Therapeutics Inc ANTX.O:
AN2 THERAPEUTICS COMMENCES FIRST-IN-HUMAN CLINICAL TRIAL OF ORAL AN2-502998 FOR CHAGAS DISEASE
AN2 THERAPEUTICS - PHASE 2 PLANNING UNDERWAY WITH DNDI COLLABORATION; INITIATION EXPECTED IN 2026, DATA IN 2027
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing.TradingKey
11 hours ago
.jpg)
Investing in Quantum Computing
TradingKey - What was once confined to university labs and science fiction books is now becoming one of the most disruptive technologies of the next twenty years, set to transform industries from pharmaceuticals and materials science to finance, logistics, and climate modeling.TradingKey
17 hours ago
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.TradingKey
Wed, Aug 13
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,TradingKey
Wed, Jul 23
